{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:00:15Z","timestamp":1787979615690,"version":"build-2784847793"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,2,10]],"date-time":"2009-02-10T00:00:00Z","timestamp":1234224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"},{"start":{"date-parts":[[2009,2,10]],"date-time":"2009-02-10T00:00:00Z","timestamp":1234224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematopathol"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1007\/s12308-009-0023-2","type":"journal-article","created":{"date-parts":[[2009,2,9]],"date-time":"2009-02-09T11:19:28Z","timestamp":1234178368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia"],"prefix":"10.1007","volume":"2","author":[{"given":"Sheeja T.","family":"Pullarkat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H.","family":"Kroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla S.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad N.","family":"Ahsanuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen P.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maung","family":"Thein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne W.","family":"Grody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell K.","family":"Brynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,2,10]]},"reference":[{"key":"23_CR1","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW eds (2008) WHO classification of tumors of haematopoietic and lymphoid tissues. IARC, Lyon"},{"key":"23_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1040-8428(02)00003-3","volume":"45","author":"N Asou","year":"2003","unstructured":"Asou N (2003) The role of a Runt domain transcription factor AML1\/RUNX1 in leukemogenesis and its clinical implications. Crit Rev Oncol Hematol 45:129\u2013150","journal-title":"Crit Rev Oncol Hematol"},{"key":"23_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc989","volume":"3","author":"DG Tenen","year":"2003","unstructured":"Tenen DG (2003) Disruption of differentiation in human cancer. AML shows the way. Nat Rev Cancer 3:89\u2013101","journal-title":"Nat Rev Cancer"},{"key":"23_CR4","doi-asserted-by":"publisher","first-page":"10398","DOI":"10.1073\/pnas.171321298","volume":"98","author":"Y Yuan","year":"2001","unstructured":"Yuan Y, Zhou L, Miyamoto T et al (2001) AML-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 98:10398\u201310403","journal-title":"Proc Natl Acad Sci USA"},{"key":"23_CR5","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1073\/pnas.0408831102","volume":"102","author":"YY Wang","year":"2005","unstructured":"Wang YY, Zhou GB, Yin T et al (2005) AML1-ETO and C-KIT mutation\/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 102:1104\u20131109","journal-title":"Proc Natl Acad Sci USA"},{"key":"23_CR6","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.4161\/cc.4.12.2256","volume":"4","author":"F Kuchenbauer","year":"2005","unstructured":"Kuchenbauer F, Feuring-Buske M, Buske C (2005) AML1-ETO needs a partner. Cell Cycle 4:1716\u20131718","journal-title":"Cell Cycle"},{"key":"23_CR7","doi-asserted-by":"publisher","first-page":"9506","DOI":"10.1073\/pnas.1531730100","volume":"100","author":"JL Grisolano","year":"2001","unstructured":"Grisolano JL, O\u2019Neal J, Cain J, Tomasson MH (2001) An activated receptor tyrosine kinase, TEL\/PDGF cooperates with AML1\/ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 100:9506\u20139511","journal-title":"Proc Natl Acad Sci USA"},{"key":"23_CR8","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1182\/blood.V96.6.2108","volume":"96","author":"KL Rhoades","year":"2000","unstructured":"Rhoades KL, Hetherington CJ, Harakawa N et al (2000) Analysis of the role of AML-ETO in leukemogenesis using an inducible transgeneic mouse model. Blood 96:2108\u20132115","journal-title":"Blood"},{"key":"23_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/ajh.10322","volume":"73","author":"VA Pullarkat","year":"2003","unstructured":"Pullarkat VA, Bueso-Ramos C, Lai R et al (2003) Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol 73:12\u201317","journal-title":"Am J Hematol"},{"key":"23_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000048186","volume":"127","author":"WR Sperr","year":"2002","unstructured":"Sperr WR, Horny H-P, Valent P (2002) Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol 127:140\u2013142","journal-title":"Int Arch Allergy Immunol"},{"key":"23_CR11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/10428190009058500","volume":"37","author":"WR Sperr","year":"2000","unstructured":"Sperr WR, Horny HP, Lechner K, Valent P (2000) Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma 37:473\u2013486","journal-title":"Leuk Lymphoma"},{"key":"23_CR12","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/1097-0142(19880901)62:5<965::AID-CNCR2820620520>3.0.CO;2-M","volume":"62","author":"WD Travis","year":"1988","unstructured":"Travis WD, Li CY, Yam LT, Bergstralh EJ, Swee RG (1988) Significance of systemic mast cell disease with associated hematologic disorders. Cancer 62:965\u2013972","journal-title":"Cancer"},{"key":"23_CR13","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S0046-8177(85)80252-5","volume":"16","author":"HP Horny","year":"1985","unstructured":"Horny HP, Parwaresch MR, Lennert K (1985) Bone marrow findings in systemic mastocytosis. Human Pathol 16:808\u2013814","journal-title":"Human Pathol"},{"key":"23_CR14","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1182\/blood-2005-09-3640","volume":"107","author":"R Cairoli","year":"2006","unstructured":"Cairoli R, Beghini A, Grillo G et al (2006) Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 107:3463\u20133468","journal-title":"Blood"},{"key":"23_CR15","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1200\/JCO.2006.06.9500","volume":"24","author":"P Paschka","year":"2006","unstructured":"Paschka P, Marcucci G, Ruppert AS et al (2006) Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv (16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 24:3904\u20133911","journal-title":"J Clin Oncol"},{"key":"23_CR16","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1182\/blood-2005-04-1466","volume":"107","author":"S Schnittger","year":"2006","unstructured":"Schnittger S, Kohl TM, haferlach T, Kern W, Hiddemann W, Spiekermann K, Schoch C (2006) KIT-D816 mutation in AML1-ETO positive AML are associated with impaired event-free and overall survival. Blood 107:1791\u20131799","journal-title":"Blood"},{"key":"23_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/ajh.2830380319","volume":"28","author":"KF Wong","year":"1991","unstructured":"Wong KF, Chan JKC, Chan JCW, Kwong YL, Ma SK, Chow TC (1991) Concurrent acute myeloid leukemia and systemic mastocytosis. Am J Hematol 28:243\u2013244","journal-title":"Am J Hematol"},{"key":"23_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jaci.2004.02.042","volume":"114","author":"L Escribano","year":"2004","unstructured":"Escribano L, Garcia-Montero A, Nunez-Lopez R et al (2004) Systemic mastocytosis associated with acute myeloid leukemia: case report and implications for disease pathogenesis. J Allergy Clin Immunol 114:28\u201333","journal-title":"J Allergy Clin Immunol"},{"key":"23_CR19","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1136\/jcp.2003.012864","volume":"57","author":"HW Bernd","year":"2004","unstructured":"Bernd HW, Sotlar K, Lorenzen J et al (2004) Acute myeloid leuke mia with t(8;21) associated with \u201coccult\u201d mastocytosis. Report of an unusual case and review of the literature. J Clin Pathol 57:324\u2013328","journal-title":"J Clin Pathol"},{"key":"23_CR20","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.exphem.2007.08.016","volume":"35","author":"S Nagai","year":"2007","unstructured":"Nagai S, Ichikawa M, Takahashi T, Sato H, Yokota H, Oshima K, Izutsu K et al (2007) The origin of neoplastic mast cells in systemic mastocytosis with AML1\/ETO positive acute myeloid leukemia. Exp Hematol 35:1747\u20131752","journal-title":"Exp Hematol"},{"key":"23_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.leukres.2006.03.006","volume":"31","author":"V Pullarkat","year":"2007","unstructured":"Pullarkat V, Bedell V, Kim Y et al (2007) Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res 31:261\u2013265","journal-title":"Leuk Res"},{"key":"23_CR22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1309\/JVALJNL4ELQMD536","volume":"128","author":"J De","year":"2007","unstructured":"De J, Zanjani R, Hibbard M et al (2007) Immunophenotype profile predictive of KIT activating mutations in AML-ETO leukemia. Am J Clin Path 128:550\u2013557","journal-title":"Am J Clin Path"},{"key":"23_CR23","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1006\/bcmd.1998.0191","volume":"24","author":"A Beghini","year":"1998","unstructured":"Beghini A, Cairoli R, Morra E, Larriza L (1998) In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying novel activating ligand-independent c-kit mutation. Blood Cells Mol Dis 24:262\u2013270","journal-title":"Blood Cells Mol Dis"},{"key":"23_CR24","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V95.2.726","volume":"95","author":"A Beghini","year":"2000","unstructured":"Beghini A, Peterlongo P, Ripamonti CB et al (2000) C-Kit mutations in core binding factor leukemias [letter]. Blood 95:726\u2013727","journal-title":"Blood"},{"key":"23_CR25","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/sj.leu.2403803","volume":"19","author":"T Nanri","year":"2005","unstructured":"Nanri T, Matsuno N, Kawakita T, Suzushima H, Kawano F, Mitsuya H, Asou N (2005) Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21) (q22;q22). Leukemia 19:1361\u20131366","journal-title":"Leukemia"},{"key":"23_CR26","doi-asserted-by":"publisher","first-page":"6787","DOI":"10.1158\/1078-0432.CCR-05-1064","volume":"11","author":"WR Sperr","year":"2005","unstructured":"Sperr WR, Drach J, Hauswirth AW et al (2005) Myelomastocytic Leukemia: evidence for the origin of mast cells from the leukemia clone and eradication by allogeneic stem cell transplantation. Clin Cancer Res 11:6787\u20136792","journal-title":"Clin Cancer Res"},{"key":"23_CR27","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1200\/JCO.2005.15.610","volume":"23","author":"G Marcucci","year":"2003","unstructured":"Marcucci G, Mrozek K, Ruppert AS et al (2003) Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 23:5705\u20135717","journal-title":"J Clin Oncol"},{"issue":"8","key":"23_CR28","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.1182\/blood-2007-07-103291","volume":"111","author":"F Dayyani","year":"2008","unstructured":"Dayyani F, Wang J, Yeh J-R J (2008) Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperate with AML1-ETO to affect myeloid cell proliferation and survival. Blood 111(8):4338\u20134347","journal-title":"Blood"},{"key":"23_CR29","first-page":"4173","volume":"58","author":"CD Bloomfield","year":"1998","unstructured":"Bloomfield CD, Lawrence D, Byrd JC et al (1998) Frequency of prolonged remission duration after high dose cytorabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173\u20134179","journal-title":"Cancer Res"},{"key":"23_CR30","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1200\/JCO.1999.17.12.3767","volume":"17","author":"JC Byrd","year":"1999","unstructured":"Byrd JC, Dodge RK, Carroll A et al (1999) Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17:3767\u20133775","journal-title":"J Clin Oncol"},{"key":"23_CR31","first-page":"1115","volume":"1","author":"MJ Frost","year":"2002","unstructured":"Frost MJ, Ferrao PT, Hughes TP, Ashman LK (2002) Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI 571) compared with wild-type c-KIT whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 1:1115\u20131124","journal-title":"Mol Cancer Ther"},{"key":"23_CR32","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","volume":"108","author":"NP Shah","year":"2006","unstructured":"Shah NP, Lee FY, Luo R et al (2006) Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108:286\u2013291","journal-title":"Blood"},{"key":"23_CR33","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1600-0609.2008.01048.x","volume":"80","author":"D Purtill","year":"2008","unstructured":"Purtill D, Cooney J, Sinnah R et al (2008) Dasatinib therapy for systemic mastocytosis: four cases. Eur J Haematol 80:456\u2013458","journal-title":"Eur J Haematol"},{"key":"23_CR34","doi-asserted-by":"crossref","unstructured":"Ustun C, Corless CL, Savage N et al (2008) Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res (Epub ahead of print)","DOI":"10.1016\/j.leukres.2008.09.027"},{"key":"23_CR35","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","volume":"106","author":"J Gotlib","year":"2005","unstructured":"Gotlib J, Berube C, Growney JD et al (2005) Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106:2865\u20132870","journal-title":"Blood"},{"key":"23_CR36","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/sj.leu.2403887","volume":"19","author":"N Von Bubnoff","year":"2005","unstructured":"Von Bubnoff N, Gorantla SHP, Kancha RK et al (2005) The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 19:1670\u20131671","journal-title":"Leukemia"}],"container-title":["Journal of Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-009-0023-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12308-009-0023-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s12308-009-0023-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-009-0023-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T19:59:21Z","timestamp":1630439961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12308-009-0023-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,10]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["23"],"URL":"https:\/\/doi.org\/10.1007\/s12308-009-0023-2","relation":{},"ISSN":["1865-5785","1865-5785"],"issn-type":[{"value":"1865-5785","type":"print"},{"value":"1865-5785","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,10]]},"assertion":[{"value":"16 October 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"27"}}